CCR2 and neoplasm: By contrast, combining the oral CCR2 small-molecule antagonist PF-04136309 with conventional chemotherapy resulted in partial tumor responses (49%) with local tumor control in 97% of patients with advanced pancreatic ductal adenocarcinoma (PDAC).